Hematologic Malignancies

Click here for RSS
Latest News
Ibrutinib (Imbruvica) and idelalisib (Zydelig) have become standard of care treatments for patients with relapsed or high-risk chronic lymphocytic leukemia, with ongoing studies in progress to move ibrutinib into the frontline... Read More >>
View Free CME from PER
top border
top border
Featured Programs
2015 ASH Annual Meeting Highlights
Gina Columbus highlights findings from the 2015 American Society of Hematology Annual Meeting and Exposition, including advances in multiple myeloma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia.View Now
Update on Use of Immunotherapy in Hematologic Malignancies
This Peer Exchange discussion, moderated by Myron Czuczman, MD, highlights the most up-to-date information available on the use of immunotherapy, past and present, in patients with lymphoma, myeloma, and leukemia. View Now

 

Immunotherapy and Oncology

Anti-Angiogenic Therapy in Lung and GI Cancers

Anti-Angiogenic Therapy in Lung and GI Cancers
Mark Socinski, MD, moderates this OncLive Peer Exchange panel discussion on modern use of anti-angiogenic therapy. The experts in gastrointestinal and lung cancers include Johanna C. Bendell, MD; Edward Garon, MD; Roy Herbst, MD; Yelena Y. Janjigian, MD; and Manish Shah, MD.
View Now
Vincent T. DeVita Jr MD
In The Death of Cancer, written by Vincent T. DeVita Jr, MD, a pioneering oncologist reveals, after 50 years on the front lines of medicine, why the war on cancer is winnable, and how to get there.